Nothing Special   »   [go: up one dir, main page]

PT3456721T - Método de produção de compostos possuindo atividade inibitória de integrase de vih - Google Patents

Método de produção de compostos possuindo atividade inibitória de integrase de vih

Info

Publication number
PT3456721T
PT3456721T PT182035899T PT18203589T PT3456721T PT 3456721 T PT3456721 T PT 3456721T PT 182035899 T PT182035899 T PT 182035899T PT 18203589 T PT18203589 T PT 18203589T PT 3456721 T PT3456721 T PT 3456721T
Authority
PT
Portugal
Prior art keywords
inhivitory
activity
hiv integrase
producing compounds
compounds
Prior art date
Application number
PT182035899T
Other languages
English (en)
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PT3456721T publication Critical patent/PT3456721T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94Oxygen atom, e.g. piperidine N-oxide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
PT182035899T 2010-08-05 2011-08-04 Método de produção de compostos possuindo atividade inibitória de integrase de vih PT3456721T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010175899 2010-08-05
JP2010277713 2010-12-14

Publications (1)

Publication Number Publication Date
PT3456721T true PT3456721T (pt) 2021-05-04

Family

ID=45559561

Family Applications (3)

Application Number Title Priority Date Filing Date
PT182035899T PT3456721T (pt) 2010-08-05 2011-08-04 Método de produção de compostos possuindo atividade inibitória de integrase de vih
PT118146901T PT2602260T (pt) 2010-08-05 2011-08-04 Processo para preparar composto possuindo atividade inibidora de integrase do vih
PT16190894T PT3127908T (pt) 2010-08-05 2011-08-04 Processo para preparar composto possuindo atividade inibidora de integrase do vih

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT118146901T PT2602260T (pt) 2010-08-05 2011-08-04 Processo para preparar composto possuindo atividade inibidora de integrase do vih
PT16190894T PT3127908T (pt) 2010-08-05 2011-08-04 Processo para preparar composto possuindo atividade inibidora de integrase do vih

Country Status (18)

Country Link
US (8) US20140011995A1 (pt)
EP (3) EP2602260B1 (pt)
JP (1) JP5636054B2 (pt)
CN (3) CN103154004B (pt)
BR (1) BR112013002461A2 (pt)
CY (1) CY1124582T1 (pt)
DK (1) DK3456721T3 (pt)
ES (3) ES2608377T3 (pt)
HR (1) HRP20210748T1 (pt)
HU (1) HUE054473T2 (pt)
LT (1) LT3456721T (pt)
PL (1) PL3456721T3 (pt)
PT (3) PT3456721T (pt)
RS (1) RS61796B1 (pt)
SG (1) SG187683A1 (pt)
SI (1) SI3456721T1 (pt)
TW (1) TWI510451B (pt)
WO (1) WO2012018065A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192550A1 (en) 2008-07-25 2013-08-30 Viiv Healthcare Co Chemical compounds
ES2641765T3 (es) 2008-12-11 2017-11-13 Shionogi & Co., Ltd. Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンhivインテグラーゼ阻害剤の製造方法および中間体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN103154004B (zh) * 2010-08-05 2016-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的化合物的制造方法
EA037633B1 (ru) 2012-12-21 2021-04-23 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
CA2916993C (en) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (pt) 2013-07-12 2018-07-21
US9856271B2 (en) * 2014-01-21 2018-01-02 Laurus Labs Limited Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
CN106866701B (zh) * 2014-03-19 2019-03-19 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (pt) 2014-06-20 2018-06-23
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
US10150780B2 (en) 2014-12-09 2018-12-11 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as HIV integrase inhibitors
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CN104557686A (zh) * 2014-12-29 2015-04-29 徐俊烨 一种吡啶酮类化合物的合成方法
EP3045461A1 (en) * 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
BR112017020837A2 (pt) 2015-04-02 2018-07-03 Gilead Sciences, Inc. compostos de carbamoilpiridona policíclicos e seu uso farmacêutico
US10696636B2 (en) 2015-12-21 2020-06-30 Lupin Limited Process for the preparation of HIV integrase inhibitors
EP3474857A4 (en) * 2016-06-23 2020-03-18 VIIV Healthcare Company COMPOSITIONS AND METHODS FOR RELEASE OF THERAPEUTIC AGENTS
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018229798A1 (en) * 2017-06-13 2018-12-20 Cipla Limited Process for the preparation of bictegravir and intermediate thereof
KR102714478B1 (ko) 2017-10-06 2024-10-10 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체의 입체 선택적인 제조 방법
CN108101838B (zh) * 2017-12-18 2020-10-20 安徽唯诗杨信息科技有限公司 一种度鲁特韦中间体的合成方法及其有关物质检测方法
US11634431B2 (en) 2018-07-12 2023-04-25 Laurus Labs Limited Process for purification of protected polycyclic carbamoylpyridone derivatives
SG11202104117WA (en) 2018-10-22 2021-05-28 Univ Nebraska Antiviral prodrugs and nanoformulations thereof
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
CN110128448A (zh) * 2019-05-22 2019-08-16 博诺康源(北京)药业科技有限公司 一种度鲁特韦原料及中间体中非对映异构体杂质的合成方法
CN110396099A (zh) * 2019-05-22 2019-11-01 博诺康源(北京)药业科技有限公司 一种度鲁特韦原料中非对映异构体杂质的合成方法
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CN110698473B (zh) * 2019-10-08 2020-12-18 浙江大学 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
CA3166480A1 (en) 2020-02-24 2021-09-02 Lan Jiang Tetracyclic compounds for treating hiv infection
CN111620891B (zh) * 2020-05-27 2023-07-14 上海启讯医药科技有限公司 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途
WO2022107755A1 (ja) 2020-11-17 2022-05-27 塩野義製薬株式会社 新規アクリジニウム塩およびその製造方法
CN112480007B (zh) * 2020-12-08 2022-11-18 宿迁市科莱博生物化学有限公司 一种1,3-二甲基-1h-吡唑-4-羧酸的合成方法
HRP20231654T1 (hr) 2021-01-19 2024-03-15 Gilead Sciences, Inc. Supstituirani spojevi piridotriazina i njihove uporabe
CN115572257B (zh) * 2021-06-21 2024-07-09 江西帝劢药业有限公司 一种吡啶酮类化合物的合成方法
WO2023175386A2 (en) * 2021-10-08 2023-09-21 Laurus Labs Limited Processes for preparation of cabotegravir or its pharmaceutically acceptable salts thereof
TWI843506B (zh) 2022-04-06 2024-05-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769380A (en) 1983-04-29 1988-09-06 Merrell Dow Pharmaceuticals Inc. Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates
JP4436229B2 (ja) 2004-10-20 2010-03-24 株式会社沖データ 電子装置
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
EP3284520B1 (en) 2005-04-28 2019-06-05 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP5297105B2 (ja) 2008-07-04 2013-09-25 株式会社クボタ 乗用型田植機
JP4975690B2 (ja) 2008-07-07 2012-07-11 アルファフーズ株式会社 レトルト食品の製造方法
PT2320908E (pt) * 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP2010068253A (ja) 2008-09-10 2010-03-25 Sony Corp 暗号処理装置
JP2010068262A (ja) 2008-09-11 2010-03-25 New Japan Radio Co Ltd 電子ボリウム
JP2010067176A (ja) 2008-09-12 2010-03-25 Nec Corp 情報処理装置
US8710249B2 (en) 2008-12-11 2014-04-29 Shionogi & Co., Ltd. Maltol ether processes and intermediates
ES2641765T3 (es) * 2008-12-11 2017-11-13 Shionogi & Co., Ltd. Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
JP5572168B2 (ja) * 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンhivインテグラーゼ阻害剤の製造方法および中間体
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI582097B (zh) * 2010-03-23 2017-05-11 Viiv醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN103154004B (zh) * 2010-08-05 2016-07-06 盐野义制药株式会社 具有hiv整合酶抑制活性的化合物的制造方法

Also Published As

Publication number Publication date
TWI510451B (zh) 2015-12-01
JP5636054B2 (ja) 2014-12-03
US10000508B2 (en) 2018-06-19
ES2710609T3 (es) 2019-04-26
US10125147B2 (en) 2018-11-13
CN106046022A (zh) 2016-10-26
US9802959B2 (en) 2017-10-31
ES2608377T3 (es) 2017-04-10
CY1124582T1 (el) 2022-07-22
CN106083891B (zh) 2018-03-23
EP3456721B1 (en) 2021-02-24
DK3456721T3 (da) 2021-04-26
BR112013002461A2 (pt) 2016-05-24
US20180044351A1 (en) 2018-02-15
CN103154004A (zh) 2013-06-12
WO2012018065A1 (ja) 2012-02-09
PT3127908T (pt) 2019-02-04
LT3456721T (lt) 2021-07-12
US9321789B2 (en) 2016-04-26
EP3456721A2 (en) 2019-03-20
EP3127908B1 (en) 2018-11-28
EP2602260A1 (en) 2013-06-12
US20180037592A1 (en) 2018-02-08
US9650394B2 (en) 2017-05-16
ES2870006T3 (es) 2021-10-26
CN106083891A (zh) 2016-11-09
SG187683A1 (en) 2013-03-28
EP3456721A3 (en) 2019-03-27
PT2602260T (pt) 2016-12-27
CN106046022B (zh) 2018-06-19
US20180037591A1 (en) 2018-02-08
US20180037593A1 (en) 2018-02-08
US20150038702A1 (en) 2015-02-05
US20140011995A1 (en) 2014-01-09
US20160229870A1 (en) 2016-08-11
US20170240564A1 (en) 2017-08-24
RS61796B1 (sr) 2021-06-30
EP3127908A2 (en) 2017-02-08
HUE054473T2 (hu) 2021-09-28
EP2602260A4 (en) 2014-01-01
US9969750B2 (en) 2018-05-15
PL3456721T3 (pl) 2021-10-25
US10125146B2 (en) 2018-11-13
SI3456721T1 (sl) 2021-05-31
HRP20210748T1 (hr) 2021-06-25
CN103154004B (zh) 2016-07-06
EP3127908A3 (en) 2017-02-15
EP2602260B1 (en) 2016-09-28
JPWO2012018065A1 (ja) 2013-10-03
TW201210990A (en) 2012-03-16

Similar Documents

Publication Publication Date Title
LT3456721T (lt) Junginių, pasižyminčių živ integrazės inhibavimo aktyvumu, gavimo būdas
IL268953B (en) A process to form cycloalkylcarboxamido indole compounds
HK1197400A1 (zh) 治療 的化合物
ZA201303568B (en) Method of producing a ppi-containing pharmaceutical preparation
PL2609120T3 (pl) Ulepszony sposób wytwarzania sugammadeksu
IL248217B (en) A method for the production of inganol-3-englate
EP2745235A4 (en) METHOD FOR REPOSITIONING MEDICATION
GB201004876D0 (en) Process for the preparation of vitamin K2
HK1184787A1 (en) Production method of intermediate compound for synthesizing medicament
EP2552915A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF HIV
HUP1000638A2 (en) Process for preparation of rosuvastatin salts
HK1186172A1 (zh) 製備 -氟- -羥基亞甲基- -氧代丁酸酯的烯醇鹽方法
ZA201300083B (en) New drug combinations for the treatment of malaria
HK1171020A1 (en) Process for preparation of pyrimidinylpyrazole compounds
EP2537851A4 (en) PROCESS FOR PREPARING B-GLYCOSIDE COMPOUNDS
HK1201062A1 (en) Process for the preparation of a statin precursor
GB201019078D0 (en) Process for the preparation of rosuvastatin
AU2011905331A0 (en) Treatment of seborrhoea
PL391571A1 (pl) Sposób otrzymywania katalizatorów oksyalkilenowania
EP2593120A4 (en) METHOD FOR THE TREATMENT OF HIV OR AIDS
HUP1000616A2 (en) Process for preparation of rosuvastatin salt
TWM386114U (en) Improved structure of punch former
EP2546235A4 (en) PROCESS FOR THE PREPARATION OF t-BUTOXYCARBONYLAMINE COMPOUNDS